Top Markets
#1 Trillions Trillions +4,372.65%
#2 Ozapay Ozapay +38.33%
#3 Aria.AI Aria.AI +21.33%
#4 TRIA TRIA +14.00%
#5 Zano Zano +12.45%
#6 Osaka Protocol Osaka Protocol +12.26%
#7 DeXe DeXe +11.85%
#8 River Pts River Pts +11.61%
#9 pippin pippin +9.94%
#10 Janction Janction +9.42%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Share Price
$0.28545656
Market Cap
$4.50M
Change (1 day)
5.97%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
P/E ratio for Acticor Biotech SAS (ALACT)
P/E ratio as of March 2026 TTM: -0.16
According to Acticor Biotech SAS latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.16. At the end of 2022 the company had a P/E ratio of -4.69.
P/E ratio history for Acticor Biotech SAS from 2010 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.16 -91.39%
2023 -1.88 -59.96%
2022 -4.69 65.91%
2021 -2.83 -51.76%
2020 -5.86 -19.83%
2019 -7.31 102.29%
2018 -3.61 60.31%
2017 -2.25 -95.44%
2016 -49.37 186.58%
2015 -17.23 -28.72%
2014 -24.17 -302.58%
2013 11.93 14.37%
2012 10.43 -24.95%
2011 13.90 -82.70%
2010 80.32 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -6,719.58%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -18,718.90%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -10,621.74%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -18,900.80%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -20,528.29%
AU
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.